Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA – PR Newswire (press release)
|
Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA
PR Newswire (press release) MOUNTAIN VIEW, Calif., Jan. 26, 2017 /PRNewswire/ — Cellecta, Inc. today announced the receipt of Phase II SBIR grant funds from the National Institute of Health (NIH) to advance development of CRISPR/Cas9 library technology. These advances improve … |
